[go: up one dir, main page]

NO20081835L - Behandlingsmetoder ved bruk av oksytocin receptoragonister - Google Patents

Behandlingsmetoder ved bruk av oksytocin receptoragonister

Info

Publication number
NO20081835L
NO20081835L NO20081835A NO20081835A NO20081835L NO 20081835 L NO20081835 L NO 20081835L NO 20081835 A NO20081835 A NO 20081835A NO 20081835 A NO20081835 A NO 20081835A NO 20081835 L NO20081835 L NO 20081835L
Authority
NO
Norway
Prior art keywords
methods
receptor agonists
treatment
oxytocin receptor
schizophrenia
Prior art date
Application number
NO20081835A
Other languages
English (en)
Inventor
Lynn Resnick
Zia Rahman
Sharon Joy Rosenzweig-Lipson
Robert H Ring
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20081835L publication Critical patent/NO20081835L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Metoder for behandling og forhindring av angst, angstrelaterte lidelser, schizofreni og schizofrenirelaterte lidelser er beskrevet her hvor nevnte metoder omfatter administrering av oksytocinreseptoragonister.
NO20081835A 2005-10-24 2008-04-16 Behandlingsmetoder ved bruk av oksytocin receptoragonister NO20081835L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72965605P 2005-10-24 2005-10-24
PCT/US2006/040425 WO2007050353A2 (en) 2005-10-24 2006-10-17 Tricyclic compounds useful as oxytocin receptor agonists

Publications (1)

Publication Number Publication Date
NO20081835L true NO20081835L (no) 2008-05-20

Family

ID=37834124

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081835A NO20081835L (no) 2005-10-24 2008-04-16 Behandlingsmetoder ved bruk av oksytocin receptoragonister

Country Status (15)

Country Link
US (1) US20070117794A1 (no)
EP (1) EP1948662A2 (no)
JP (1) JP2009512730A (no)
KR (1) KR20080063848A (no)
CN (1) CN101296929A (no)
AU (1) AU2006306547A1 (no)
BR (1) BRPI0617770A2 (no)
CA (1) CA2626180A1 (no)
CR (1) CR9923A (no)
EC (1) ECSP088398A (no)
GT (1) GT200800052A (no)
IL (1) IL190900A0 (no)
NO (1) NO20081835L (no)
RU (1) RU2008114374A (no)
WO (1) WO2007050353A2 (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011027060A2 (fr) 2009-09-04 2011-03-10 Centre National De La Recherche Scientifique - Crns - Traitement par l'ocytocine de caracteristiques comportementales associees a l'autisme et a la timidite pathologique
CN102905720A (zh) 2010-05-18 2013-01-30 日内瓦大学 催产素样分子的新用途及相关的方法
WO2011146806A1 (en) * 2010-05-21 2011-11-24 University Of Florida Research Foundation, Inc. Methods for reducing anesthetic-inducible epileptogenic and neurotoxic effects
WO2012016229A2 (en) * 2010-07-30 2012-02-02 The Regents Of The University Of California Oxytocin treatment to improve memory and modify blood glucose
US10265372B2 (en) 2014-08-12 2019-04-23 The Regents Of The University Of California Molecular composition for enhancing and rejuvenating maintenance and repair of mammalian tissues
HUE060496T2 (hu) 2015-07-06 2023-03-28 Kinoxis Therapeutics Pty Ltd Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
RU2019120162A (ru) * 2016-12-12 2021-01-12 Де Юниверсити Оф Сидней Непептидные агонисты рецепторов окситоцина
WO2019180269A1 (en) 2018-03-23 2019-09-26 Cytoo Alk5 inhibitors as skeletal muscle hypertrophy inducers

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900200B2 (en) * 2001-04-12 2005-05-31 Wyeth Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists
GB0115515D0 (en) * 2001-06-25 2001-08-15 Ferring Bv Oxytocin agonisys
GB0120051D0 (en) * 2001-08-16 2001-10-10 Ferring Bv Oxytocin agonists
EP1449844A1 (en) * 2003-02-14 2004-08-25 Ferring B.V. benzamide derivatives as oxytocin agonists and vasopressin antagonists
EP1512687A1 (en) * 2003-09-05 2005-03-09 Ferring B.V. Piperazines as oxytocin agonists

Also Published As

Publication number Publication date
JP2009512730A (ja) 2009-03-26
CR9923A (es) 2008-06-27
AU2006306547A1 (en) 2007-05-03
ECSP088398A (es) 2008-06-30
WO2007050353A2 (en) 2007-05-03
IL190900A0 (en) 2008-11-03
CA2626180A1 (en) 2007-05-03
WO2007050353A3 (en) 2007-06-21
GT200800052A (es) 2008-10-06
US20070117794A1 (en) 2007-05-24
EP1948662A2 (en) 2008-07-30
BRPI0617770A2 (pt) 2011-08-09
RU2008114374A (ru) 2009-12-10
KR20080063848A (ko) 2008-07-07
CN101296929A (zh) 2008-10-29

Similar Documents

Publication Publication Date Title
NO20081835L (no) Behandlingsmetoder ved bruk av oksytocin receptoragonister
UA109878C2 (uk) Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти)
EA201000016A1 (ru) Способы и композиции для лечения рака, опухолей и нарушений, связанных с опухолями
DE602006008456D1 (de) Amylin und amylinagonisten für die behandlung von psychiatrischen erkrankungen und störungen
CY1121135T1 (el) Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος
NO20070855L (no) Arylidener for behandling av estrogenrelaterte reseptor-alfamedierte sykdommer.
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
ATE528002T1 (de) Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA200971077A1 (ru) Гетероциклические модуляторы киназы
NO20074943L (no) Roflumilast for behandlingen av diabetes mellitus
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
SG179410A1 (en) Therapeutic uses of inhibitors of rtp801
NO20082923L (no) Anvendelse av en CB1 antagonist for behandling av bivirkninger og negative symptomer pa schizofreni
NO20092634L (no) Fremgangsmate for fremstilling av piperazinyl og diazepanyl benzamidderivater
CL2008002162A1 (es) Compuestos derivados de 3-benzoisoxazol-piperidin; composicion farmaceutica que comprende a dichos compuestos; y su uso para el tratamiento y/o prevencion de trastornos cognitivos, adiccion a drogas, depresion, ansiedad, entre otras.
MX2010006206A (es) Derivados de oxindol substituidos por 5-halogeno y el uso de los mismos para el tratamiento de enfermedades dependientes de la vasopresina.
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
AR060786A1 (es) Variaciones cristalinas de (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina
EA200802072A1 (ru) Ликопин для лечения нарушения обмена веществ
NO20091052L (no) Diaryleterderivater og anvendelser derav
ATE528309T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
ATE484501T1 (de) Als protein-kinase-inhibitoren nutzbare benzimidazole
ECSP10010379A (es) Derivados de oxindol sustituido y su uso para el tratamiento de enfermedades dependientes de la vasopresina
CY1116166T1 (el) Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application